Table of Contents
International Journal of Molecular Imaging
Volume 2013 (2013), Article ID 290750, 7 pages
http://dx.doi.org/10.1155/2013/290750
Research Article

Rhenium-188 Production in Hospitals, by W-188/Re-188 Generator, for Easy Use in Radionuclide Therapy

11st Radiology Department, National & Kapodistrian University of Athens, Athens, Greece
2Medical Physics Laboratory, School of Medicine, National & Kapodistrian University of Athens, Athens, Greece
3Radiation Physics Unit & Division of Nuclear Medicine, 1st Radiology Department, National & Kapodistrian University of Athens, Athens, Greece

Received 4 November 2012; Accepted 13 March 2013

Academic Editor: Sui Shen

Copyright © 2013 Maria Argyrou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Manual for Reactor Produced Radioisotopes, International Atomic Energy Agency, 2003.
  2. S. Mirzadeh, F. F. Knapp Jr., and A. P. Callahan, “Production of tungsten-188 and osmium-194 in a nuclear reactor for new clinical generators,” in Proceedings of the International Conference on Nuclear Data for Science and Technology, Juelich, Germany, May 1991.
  3. H. Matsuoka, K. Hashimoto, Y. Hishinuma et al., “Application of PZC to 188W/188Re generators,” Journal of Nuclear and Radiochemical Sciences, vol. 6, no. 3, pp. 189–191, 2005. View at Google Scholar
  4. M. Andreou, G. Papanikolos, G. Vamvakas, N. Kotsakis, and M. Lyra, “Site-specific dosimetry of metastatic lesions in 186Re therapy,” in Proceedings of the 10th International Conference on Information Technology and Applications in Biomedicine (ITAB), Corfu, Greece, November 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Jeong and F. F. Knapp, “Use of the Oak Ridge national laboratory tungsten-188/rhenium-188 generator for preparation of the rhenium-188 HDD/lipiodol complex for trans-arterial liver cancer therapy,” Seminars in Nuclear Medicine, vol. 38, no. 2, pp. S19–S29, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Lyra, M. Andreou, A. Georgantzoglou et al., “Radionuclides used in nuclear medicine therapy—from production to dosimetry,” Current Medical Imaging Reviews, vol. 9, no. 1, 2013. View at Google Scholar
  7. S. Chen, K. Xu, W. Liu et al., “Treatment of metastatic bone pain with rhenium-188 hydroxyethylidene diphosphonate,” Medical Principles and Practice, vol. 10, no. 2, pp. 98–101, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. P. J. Blower, A. S. Lam, O. 'Doherty MJ, A. G. Kettle, A. J. Coakley, and F. F. Knapp Jr., “Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 25, no. 6, pp. 613–621, 1998. View at Google Scholar
  9. B. Lambert, K. Bacher, and L. Defreyne, “Rhenium-188 based radiopharmaceuticals for treatment of liver tumours,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 53, no. 3, pp. 305–310, 2009. View at Google Scholar · View at Scopus
  10. B. Lambert, K. Bacher, L. Defreyne et al., “188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial,” Journal of Nuclear Medicine, vol. 46, no. 1, pp. 60–66, 2005. View at Google Scholar · View at Scopus
  11. A. Boschi, L. Uccelli, A. Duatti et al., “A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma,” Nuclear Medicine Communications, vol. 25, no. 7, pp. 691–699, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Garin, N. Noiret, C. Malbert et al., “Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 4, pp. 542–546, 2004. View at Google Scholar · View at Scopus
  13. E. Garin, B. Denizot, N. Noiret et al., “188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma,” Nuclear Medicine Communications, vol. 25, no. 10, pp. 1007–1013, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Wunderlich, J. Pinkert, M. Andreeff et al., “Preparation and biodistribution of rhenium-188 labeled albumin microspheres B 20: a promising new agent for radiotherapy,” Applied Radiation and Isotopes, vol. 52, no. 1, pp. 63–68, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Lepareur, V. Ardisson, N. Noiret, and E. Garin, “188-Re/lipiodol: development of a potential treatment for HCC from bench to bedside,” International Journal of Molecular Imaging, vol. 2012, Article ID 278306, 9 pages, 2012. View at Publisher · View at Google Scholar
  16. E. Torres-García, G. Ferro-Flores, C. Arteaga de Murphy, L. Correa-González, and P. A. Pichardo-Romero, “Biokinetics and dosimetry of 188Re-anti-CD20 in patients with non-Hodgkin’s lymphoma: preliminary experience,” Archives of Medical Research, vol. 39, no. 1, pp. 100–109, 2008. View at Google Scholar
  17. E. Kaplan, I. G. Fels, and B. R. Kotlowski, “Therapy of carcinoma of the prostate metastatic to bone with P-32 labeled condensed phosphate,” Journal of Nuclear Medicine, vol. 1, pp. 1–13, 1960. View at Google Scholar
  18. B. Lambert and J. M. H. de Klerk, “Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy,” Nuclear Medicine Communications, vol. 27, no. 3, pp. 223–229, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Bodei, M. Lam, C. Chiesa et al., “EANM procedure guideline for treatment of refractory metastatic bone pain,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 10, pp. 1934–1940, 2008. View at Publisher · View at Google Scholar
  20. M. G. Stabin, R. B. Sparks, and E. Crowe, “OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine,” Journal of Nuclear Medicine, vol. 46, no. 6, pp. 1023–1027, 2005. View at Google Scholar · View at Scopus
  21. W. S. Snyder, M. R. Ford, G. G. Warner, and S. B. Watson, S, Absorbed Dose Per Unit Cumulated Activity for Selected Radionuclides and Organs, MIRD Pamphlet no. 11, The Society of Nuclear Medicine, New York, NY, USA, 1975.
  22. W. E. Bolch, L. G. Bouchet, J. S. Robertson et al., “MIRD pamphlet no. 17: the dosimetry of nonuniform activity distributions—radionuclide S values at the voxel level,” Journal of Nuclear Medicine, vol. 40, no. 1, pp. 11S–36S, 1999. View at Google Scholar · View at Scopus
  23. K. Liepe, J. Kropp, R. Runge, and J. Kotzerke, “Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases,” British Journal of Cancer, vol. 89, no. 4, pp. 625–629, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Liepe, R. Hliscs, J. Kropp, R. Runge, F. F. Knapp Jr., and W. G. Franke, “Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases,” Journal of Nuclear Medicine, vol. 44, no. 6, pp. 953–960, 2003. View at Google Scholar · View at Scopus
  25. D. R. Fisher, “Interpreting data from medical imaging for absorbed dose calculations,” in Proceedings of the 45th Annual Meeting of the Society of Nuclear Medicine, p. 642, Toronto, Canada, June 1998.
  26. M. G. Stabin, “MIRDOSE: personal computer software for internal dose assessment in nuclear medicine,” Journal of Nuclear Medicine, vol. 37, no. 3, pp. 538–546, 1996. View at Google Scholar · View at Scopus
  27. E. Savio, J. Gaudiano, A. M. Robles et al., “Re-HEDP: pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose,” BMC Nuclear Medicine, vol. 1, article 2, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. H. R. Maxon, L. E. Schroder, L. C. Washburn et al., “Rhenium-188(Sn)HEDP for treatment of osseous metastases,” Journal of Nuclear Medicine, vol. 39, no. 4, pp. 659–663, 1998. View at Google Scholar · View at Scopus
  29. H. Palmedo, A. Manka-Waluch, P. Albers et al., “Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate,” Journal of Clinical Oncology, vol. 21, no. 15, pp. 2869–2875, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. H. J. Biersack, H. Palmedo, A. Andris et al., “Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysiss,” Journal of Nuclear Medicine, vol. 52, pp. 1721–1726, 2011. View at Publisher · View at Google Scholar
  31. M. Lyra, G. Papanikolos, P. Phinou, A. P. Frantzis, J. Jordanou, and G. S. Limouris, “Rhenium-186-HEDP dosimetry and multiple bone metastases palliation therapy effects,” in Radionuclide Therapy for Oncology Current Status and Future Aspects, 2003. View at Google Scholar
  32. G. H. Daniels and D. A. Haber, “Will radioiodine be useful in treatment of breast cancer?” Nature Medicine, vol. 6, no. 8, pp. 859–860, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Dadachova, B. Bouzahzah, L. S. Zuckier, and R. G. Pestell, “Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS),” Nuclear Medicine and Biology, vol. 29, no. 1, pp. 13–18, 2002. View at Publisher · View at Google Scholar · View at Scopus